Efficacy and Safety of Canakinumab in Schnitzler Syndrome

NCT01276522 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

8

Enrollment

OTHER

Sponsor class

Conditions

Schnitzler Syndrome

Interventions

DRUG: Canakinumab

Sponsor

Radboud University Medical Center

Collaborators

[object Object]